Second mitochondrial activator of caspase (Smac)-derived peptides have previously been shown to facilitate apoptosis of various types of cancer cells. However, it remains unclear whether the effects of such Smac agonists are dependent on apoptotic protease-activating factor-1 (Apaf-1), a key component of the apoptosome. Here, we explored the role of Apaf-1 through overexpression of this protein in the B-lymphoma cell line Raji that is defective for cytosolic Apaf-1 expression. Enforced expression of Apaf-1 rendered Raji cells sensitive to staurosporine as well as to the proteasome inhibitor, lactacystin. Importantly, co-treatment with Smac peptides resulted in a threefold higher degree of apoptosis in Apaf-1-expressing Raji cells, but not in mock-transfected cells. Smac peptides also potentiated apoptosis of the DG-75 cell line following liberation of endogenous Apaf-1 from the plasma membrane, but were ineffective when added alone. Furthermore, we observed high levels of expression in several B-lymphoma cell lines of cellular inhibitor of apoptosis protein-2 (cIAP2), and immunodepletion of cIAP2 (a target of Smac) was found to sensitize Apaf-1-overexpressing Raji cells to cytochrome c-dependent caspase activation. Collectively, these results demonstrate the importance of Apaf-1 in Smac-mediated potentiation of apoptosis of B-lymphoma-derived cells.
Introduction
Chemotherapeutic agents and many other forms of cellular stress induce apoptosis through the so-called intrinsic pathway, which involves mitochondrial integration of cell death signals and subsequent release of apoptogenic factors, including cytochrome c, into the cytosol. 1 Cytochrome c then initiates formation of the apoptosome complex, consisting of apoptotic protease-activating factor-1 (Apaf-1) and pro-caspase-9, leading to the activation of caspase-9, which in turn activates downstream caspases such as caspase-3. The inhibitor of apoptosis proteins (IAPs) are molecules which suppress apoptosis through direct binding and inhibition of several effector caspases; the IAPs themselves are subject to regulation by second mitochondrial activator of caspase (Smac), a protein that is released from mitochondria during apoptosis and serves to antagonize the binding of IAPs to caspases. 2 Recent studies have shown that cell-permeable, N-terminal Smac peptides are able to sensitize various types of cancer cells to apoptosis triggered by death receptor ligation or chemotherapeutic agents. [3] [4] [5] However, it remains unresolved whether agonistic Smac peptides are dependent on the formation of a functional apoptosome. Hence, Apaf-1-deficient melanoma cells were reported to respond to synthetic Smac peptides, 3 although other investigators found that certain leukemia cells devoid of Apaf-1 failed to do so. 5 Moreover, recent studies support the existence of an Apaf-1-independent pathway of caspase-9 activation, acting via Smac-mediated elimination of X-linked IAP (XIAP), in cells obtained from multiple myeloma patients. 6 Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin's lymphoma characterized at the molecular genetic level by chromosomal rearrangements of the c-myc oncogene. 7 We and others have shown that BL-derived B cell lines frequently are resistant to apoptosis, [8] [9] [10] and we have recently provided evidence that ectopic, noncytosolic localization of Apaf-1 may function as a novel mechanism of chemoresistance in these cells. 11 Enforced expression of exogenous Apaf-1 or disruption of lipid raft domains with subsequent liberation of endogenous Apaf-1 rendered these cells chemosensitive. The present studies, using BL cell lines as a model system, demonstrate that Apaf-1 is required for Smac-dependent potentiation of staurosporine (STS)-and lactacystin-triggered apoptosis. Moreover, immunodepletion of cIAP2 sensitized these cells to caspase activation in a manner dependent upon cytosolic Apaf-1 expression. These findings have important implications for the harnessing of apoptosis-targeted drugs, including proteasome inhibitors and Smac agonists, in the treatment of human malignancies.
Materials and methods

Reagents
Lactacystin and STS were purchased from Calbiochem (San Diego, CA, USA) and Sigma (St Louis, MO, USA), respectively. Hoechst 33342 was obtained from Molecular Probes (Leiden, The Netherlands), benzyloxy-carbonyl-valine-alanine-aspartatefluoromethyl-ketone (zVAD-fmk) from Enzyme Systems Products (Dublin, CA, USA), and aspartate-glutamate-valine-aspartate-amino-coumarin (DEVD-AMC) from Biomol (Plymouth Meeting, PA, USA). Antibodies to the following proteins were used: b-actin (Sigma), Apaf-1 (Chemicon, Temecula, CA, USA), cIAP1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), cIAP2 (R&D Systems, Minneapolis, MN, USA), GAPDH (Trevigen, Gaithersburg, MD, USA), and XIAP (Nordic Biosite, Täby, Sweden).
Smac peptides
Cell-permeable 7-mer peptides corresponding to the N-terminal sequence of Smac (AVPIAQK) linked to the 16-mer Drosophila antennapedia penetration sequence (RQIKIWFQNRRMKWKK) were obtained from Calbiochem. The purity of the peptide as determined by high-performance liquid chromatography (HPLC) was 495%. Solvent alone (i.e. dimethylsulfoxide (DMSO)) was used as a control. For some experiments, fluorescein isothiocyanate (FITC)-conjugated peptides were employed. To this end, peptides consisting of the first eight N-terminal amino acids of Smac (AVPIAQKS) or a scrambled version of the same sequence (SKIPAQVA), the antennapedia penetration sequence, and FITC were custom-synthesized (Peptide Institute Inc., Osaka, Japan). The purity of these peptides as determined by HPLC was 492%. The stock solutions of FITC-conjugated peptides were prepared in distilled water. Cellular uptake of peptides was visualized using a Nikon Eclipse TE2000 microscope (Nikon Instruments, Badhoeverdorp, The Netherlands) equipped with a DS-5M digital camera operating with NIS elements software.
Cell culture
The BL-derived human B cell lines Raji, DG-75, Ramos, Mutu I and Mutu III were obtained from the cell culture collections of the Microbiology and Tumor Biology Center (Karolinska Institutet, Stockholm, Sweden). Epstein-Barr virus (EBV) status and p53 status for these cell lines are shown in Table 1 . The Jurkat T cell line was from the European Cell Culture Collection (Salisbury, UK). All cell lines were maintained in a humidified 5% CO 2 atmosphere in RPMI-1640 medium (Life Technologies, Paisley, Scotland) supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 1 mM glutamine and 10% fetal bovine serum.
Generation of stable cell lines
Apaf-1 pcDNA3.1 (À) plasmid (the generous gift of Dr Xiaodong Wang, University of Texas Southwestern Medical Center, Dallas, TX, USA) was grown in Escherichia coli XL-1 blue strain and purified using the Plasmid DNA MiniPrep kit (Qiagen, Valencia, CA, USA). Raji BL cell lines stably overexpressing Apaf-1 were obtained by electroporation with Apaf-1 pcDNA3.1 (À) using a BioRad Gene Pulser and isolation of stable clones was performed after 3 weeks of selection in geneticin (Life Technologies).
Morphological assessment of apoptosis
Cytocentrifuged cells were stained with 10 mg/ml Hoechst 33342 and apoptotic features (fragmented/condensed nuclei) were determined using an Olympus BX60 fluorescence microscope (Olympus, Hamburg, Germany). On average 900-1200 cells were examined for each condition.
Flow cytometric determination of apoptosis
Cell death was measured by forward light scatter analysis as reported previously 10 using a FACScan (Becton Dickinson, San Jose, CA, USA) operating with CellQuest software (Becton Dickinson). In addition, phosphatidylserine (PS) exposure was determined by flow cytometric detection of the PS-binding protein annexin V using the protocol outlined in the annexin V-FITC apoptosis detection kit (Oncogene Research Products, Cambridge, MA, USA). Briefly, cells were harvested, washed and resuspended in a HEPES buffer containing annexin V-FITC and propidium iodide (PI) (100 mg/ml) before analysis on a FACScan (Becton Dickinson), as described previously. 10 Cellular uptake of FITC-conjugated Smac and control peptides (see section above) was also assessed using a FACScan operating with CellQuest software (Becton Dickinson).
Caspase activity measurements
Cell lysates were combined with the fluorogenic, caspase-3-specific substrate, DEVD-AMC, in a standard reaction buffer 12 and real-time measurements of enzyme-catalyzed release of AMC were obtained using a Fluoroscan II plate reader (Labsystems, Stockholm, Sweden). Fluorescence values were converted to picomoles of AMC release using a standard curve generated with free AMC, and the maximum rate of AMC release (pmol/min) was estimated for each sample.
Immunoprecipitation and cell-free reactions
Purified rabbit anti-cIAP2 antibodies were used for immunoprecipitation. Briefly, protein G sepharose 4FL beads (Amersham Biosciences, Buckinghamshire, UK) were incubated overnight with S-100 cytosols and the specific primary antibody, as indicated. Immunoprecipitates were collected by centrifugation and denatured by boiling in Laemmli's buffer before immunoblotting. Supernatants (i.e. immunodepleted cytosolic extracts) were incubated with cytochrome c and 2 0 -deoxyadenosine 5 0 -triphosphate (dATP; Sigma) for 30 min at 301C and assessed for caspase-3-like activity as described previously. 
Western-blot analysis
Mitochondrial and cytosolic fractions, or total cellular extracts, were obtained as reported previously. 11 Equal amounts of protein were determined using the Bradford reagent (BioRad Laboratories, Hercules, CA, USA) and samples (30 mg) were subjected to standard sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by transfer to nitrocellulose membranes. Immunoblotting was performed with the indicated primary antibodies, and proteins were visualized by SuperSignal enhanced chemiluminescence (Pierce, Rockford, IL, USA) using the LAS 1000 þ luminescent image analysis system (Fujifilm, Stockholm, Sweden). The purity of the subcellular fractions was confirmed using antibodies to cytochrome c oxidase subunit IV (COX IV) (Molecular Probes) and bactin (data not shown). 
Results
Resistance to staurosporine-triggered (i.e. mitochondriadependent) apoptosis in B-lymphoma cell lines
Resistance to apoptosis induction by chemotherapeutic agents such as etoposide is common in BL-derived cell lines. 8, 11 To test whether this pattern of resistance extends to other apoptosis stimuli, a panel of BL cell lines were subjected to treatment with STS, a broad-spectrum protein kinase inhibitor known to engage the mitochondria-dependent apoptosis pathway. 13 As seen in Figure 1a , the Raji and DG-75 cell lines were completely resistant to STS-induced apoptosis, as determined by the degree of nuclear condensation/fragmentation. However, the Ramos cell line and the Mutu cell line variants (displaying different patterns of viral latency) 14 showed a significant degree of STSinduced apoptosis. Similar results were obtained when assaying the same panel of cell lines for cell shrinkage and PS externalization (two common features of apoptosis) (data not shown).
High level of expression of cellular inhibitor of apoptosis protein-2 in human B-lymphoma cell lines
IAPs are highly expressed in several types of human cancer and may actively contribute to the malignant phenotype of cancer cells. 2 Indeed, recent studies in Hodgkin's lymphoma-derived B cell lines have implicated high levels of XIAP in the resistance to cytochrome c-dependent induction of apoptosis. 15 We therefore tested our panel of BL-derived cell lines for expression of cIAP1, cIAP2 and XIAP. As seen in Figure 1b , the expression of cIAP2 was elevated in all lymphoma cell lines tested, as compared to the Jurkat T-cell leukemia cell line. The expression of cIAP1 and XIAP, on the other hand, was not elevated when compared to Jurkat cells. To determine whether cIAP2 plays any role in the apoptosis resistance of Raji lymphoma cells, immunoprecipitation of this protein was performed using specific antibodies.
However, cellular extracts immunodepleted for cIAP2 remained refractory to cytochrome c-dependent caspase activation (data not shown), suggesting that overexpression of cIAP2 alone does not serve as a critical determinant of apoptosis resistance in these cells.
cIAP2 immunodepletion sensitizes B-lymphoma cells to apoptosome-dependent caspase activation
We have previously shown that cytosolic expression of Apaf-1 is critical for etoposide-induced apoptosis in BL cell lines. 11 On the basis of these findings, we reasoned that elevated cytosolic levels of cIAP2 (an endogenous caspase inhibitor) might serve to modulate the threshold of sensitivity to apoptosis, in cells expressing a functional apoptosome. Therefore, we tested whether immunodepletion of cIAP2 in BL cells overexpressing Apaf-1 in the cytosolic compartment could sensitize these cells to cytochrome c-dependent apoptosis. To this end, immunoprecipitation of cIAP2 was conducted in Apaf-1-versus mocktransfected Raji cells using specific antibodies (Figure 2a) , and the resulting cytosolic extracts were assessed for cytochrome c-dependent activation of caspases. As expected, DEVD-AMC cleavage (indicative of caspase-3 activation) was seen in cell extracts derived from the Apaf-1-overexpressing cells. Moreover, immunodepletion of cIAP2 served to potentiate caspase activation in Raji cells stably overexpressing Apaf-1, but failed to do so in the mock transfectants (Figure 2b ). The differences in caspase activation between control and Apaf-1-overexpressing cells were significant (Figure 2c ). These findings thus confirm the notion that IAPs may modulate the degree of apoptosis in B-lymphoma cells that can support apoptosome complex formation.
Defective STS-induced release of endogenous Smac from mitochondria in apoptosis-resistant B-lymphoma cells
Caspase activation downstream of mitochondria is promoted by cytochrome c, a cofactor for Apaf-1 oligomerization. 1 Our previous studies have shown that cytochrome c is released from mitochondria in the chemoresistant Raji cell line. 11 We have also documented mitochondrial release of cytochrome c in the absence of downstream caspase activation in certain human leukemia cell lines. 16 However, the apoptosis-associated release 
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of cytochrome c and other proapoptotic factors does not necessarily occur via the same mechanism. 17 We therefore asked whether Smac, the second mitochondrial activator of caspases, is released into the cytosol of B-lymphoma cells. Control experiments revealed that the total amount of Smac was similar in Jurkat cells (apoptosis-sensitive) and Raji cells (apoptosis-resistant) (Figure 3a ). Raji and Jurkat cells were then treated with STS and the amount of cytochrome c and Smac in cytosolic and mitochondrial fractions was determined. Evidence of cytochrome c release from mitochondria was obtained in both cell lines (data not shown), in line with our previous findings. 11 However, although the mitochondrial fraction of Smac gradually decreased in Jurkat cells following STS treatment, the level of Smac in Raji mitochondria remained constant (Figure 3b ), thus indicating that these cells are defective for Smac release.
Potentiation of apoptosis in Apaf-1-overexpressing B-lymphoma cells by exogenous Smac peptides
Several groups have shown that exogenous N-terminal Smac peptides may potentiate apoptosis of cancer cells. [3] [4] [5] In an attempt to circumvent the apparent defect in mitochondrial Smac release in apoptosis-resistant lymphoma cells, cell-permeable Smac peptides were added to Raji cells in the presence or absence of STS. However, no apoptosis induction or potentiation was seen under these conditions (data not shown). We then utilized stable Apaf-1-transfected Raji cells or their mocktransfected counterparts. As seen in Figure 4a , incubation of Apaf-1-transfected lymphoma cells with STS resulted in a moderate degree of apoptosis. Co-incubation of these cells with Smac peptides and STS resulted in a threefold higher level of apoptosis (Figure 4a and b) . Smac peptides had no effect, however, in the mock-transfected cells. Furthermore, preincubation of cells with the pan-caspase inhibitor, zVAD-fmk, abrogated the Smac-induced potentiation of apoptosis (Figure 4a ), thus indicating that this effect was caspasedependent. To confirm that the effect of the synthetic Smac peptides was specific, custom-designed FITC-conjugated Smac and control peptides were added to Apaf-1-transfected Raji cells and the cells were then subjected to a brief course of STS treatment. The Smac peptide, but not the scrambled control 
Smac agonists sensitize Apaf-1-overexpressing B-lymphoma cells to proteasome inhibitor (lactacystin)-induced apoptosis
Proteasome inhibitors have been reported to trigger apoptosis in numerous types of human cancer cells, 18 although our understanding of the underlying signaling pathways remains incomplete. To test whether the role of Apaf-1 is confined to STSinduced apoptosis, we treated Apaf-1-or mock-transfected Raji cells with lactacystin, a potent and specific inhibitor of the proteasome. As seen in Figure 4a , lactacystin yielded a moderate level of apoptosis in lymphoma cells expressing Apaf-1, but not in the mock-transfected counterparts. Moreover, the addition of synthetic Smac peptides resulted in a threefold higher level of apoptosis in Apaf-1-expressing cells. Again, apoptosis was found to be caspase-dependent (Figure 4a ). Total cell extracts from Apaf-1-and mock-transfected Raji cells were also subjected to immunoblot analysis. As expected, the total cellular expression of Apaf-1 was increased in the stably transfected cell line; however, there were no differences in the level of cIAP2 expression between Apaf-1-and mock-transfected cells (Figure 4c) . Hence, the effect of exogenous Smac peptides in this model appeared to be related to the expression of Apaf-1 per se, and not to a compensatory decrease of IAPs following the stable overexpression of Apaf-1. Together, our findings strengthen the notion that functional or physical inhibition of IAPs may modulate the degree of apoptosis in BL cells that can support apoptosome activation.
Lipid raft disruption enables Smac-mediated potentiation of STS-and lactacystin-triggered apoptosis in B-lymphoma cells
To verify that the importance of Apaf-1 for apoptosis signaling is not limited to the Raji cell line, we utilized DG-75-lymphoma cells, that are resistant to the chemotherapeutic agent, etoposide, 10, 11 as well as to STS (the present study). Our previous studies have shown that the lipid raft-disrupting agent, methylb-cyclodextrin (MCD), can sensitize both the Raji cell line and the DG-75 cell line to cytochrome c-dependent activation of caspases, through the liberation of endogenous Apaf-1 from the plasma membrane. 11 We therefore incubated DG-75 cells in the presence or absence of MCD before the addition of STS. As seen in Figure 6a , a moderate degree of apoptosis was detected upon the combination of the lipid raft-disrupting agent and STS. MCD alone, however, did not exert any cytotoxic effects in this model. The addition of synthetic Smac peptides triggered a threefold higher level of apoptosis in DG-75 cells (Figure 6a ), whereas Smac peptides alone or Smac peptides þ STS (in the absence of MCD) showed very minor effects. Next, we tested whether exogenous Smac peptides could also potentiate the Membranes were probed with specific antibodies against Apaf-1, cIAP2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (to confirm equal loading of protein). Note that wildtype Raji cells are not completely devoid of Apaf-1; however, our previous investigations 11 have shown that Apaf-1 is sequestered in lipid raft domains of these cells.
Apaf-1-dependent Smac effects Y Sun et al degree of apoptosis induced by the proteasome inhibitor, lactacystin. Again, the combination of MCD and lactacystin yielded a moderate level of apoptosis, as evidenced by nuclear condensation/fragmentation, whereas each agent alone showed no effect (Figure 6b ). Co-cultivation of DG-75 cells with Smac peptides þ lactacystin þ MCD resulted in an almost threefold higher level of apoptosis (Figure 6b ). These results are thus consistent with our findings obtained in Apaf-1-transfected Raji cells, and suggest that Smac-mediated potentiation of STS-and lactacystin-induced apoptosis of B-lymphoma cell lines is dependent upon apoptosome activation.
Discussion
Increasing evidence indicates that resistance to apoptosis may contribute to carcinogenesis and may also confer resistance to conventional chemotherapeutic agents. 19 A promising approach to enhance the effectiveness of cancer treatment is to directly target intrinsic apoptosis signaling pathways. However, to determine which molecular targets are the most suitable for cancer therapy, a profiling of the mechanisms of resistance in cancer cells is required.
We have previously shown that the prototypic Raji lymphoma cell line lacks cytosolic expression of Apaf-1 and, hence, is resistant to etoposide-induced apoptosis. 11 Here, we provide evidence that Raji cells also fail to release the IAP-binding molecule, Smac, possibly owing to a lack of cytochrome cdependent caspase activation downstream of mitochondria, as suggested by recent studies using cytochrome c-deficient cells. 20 Of note, numerous previous reports have focused on the mechanism of release of different apoptogenic factors from mitochondria; in some cases, cytochrome c and Smac appear to escape from these organelles via the same route, whereas in other model systems, the release of Smac was found to occur downstream of cytochrome c release and caspase Apaf-1-dependent Smac effects Y Sun et al activation. 17, [21] [22] [23] We also report an elevated level of expression of cIAP2 in Raji cells, as well as in several other BL-derived cell lines. Our studies show that restoration of Apaf-1 expression through stable overexpression was sufficient to sensitize Raji cells to STS-and lactacystin-induced apoptosis. Moreover, immunodepletion of cIAP2 further increased the sensitivity of these cells to caspase activation under conditions of enforced expression of Apaf-1. Liberation of endogenous Apaf-1 into the cytosol of the DG-75 cell line through the disruption of lipid raft domains also rendered these cells susceptible to STS-and lactacystin-mediated apoptosis. Together, these findings suggest that Apaf-1 is a critical determinant of apoptosis in the human B-lymphoma cell lines studied herein, whereas other molecules, such as cIAP2, that impinge on post-mitochondrial signaling pathways may serve to modulate the amplitude of the apoptotic response.
IAPs are overexpressed in many cancer cells and these molecules have emerged as a novel target for cancer treatment. 2 Smac alleviates caspase inhibition by members of the IAP family, and Smac-derived agonistic peptides have previously been shown to sensitize cancer cells to death receptor stimulation and chemotherapeutic drugs. For instance, eradication of established tumors in mice upon combined treatment with Smac peptides and tumor necrosis factor-related apoptosisinducing ligand (TRAIL) was demonstrated in a malignant glioma xenograft model. 3 Similarly, Smac peptides in combination with cisplatin or taxol were shown to induce regression of tumor growth in nude mice bearing NCI-H460 (non-small cell lung cancer) xenografts. 24 In the current study, Smac peptides were found to potentiate apoptosis triggered by STS or lactacystin in Apaf-1-overexpressing Raji cells, but failed to do so in mock-transfected or parental cells. Similarly, Smac agonists potentiated apoptosis of STS-or lactacystin-treated DG-75 cells, following pretreatment of these cells with a lipid raft-disrupting agent. These findings provide further support for the utility of Smac agonists in cancer treatment. However, our findings caution that the ability of Smac peptides to augment apoptosis may be dependent on cancer cell expression of cytosolic Apaf-1. Similar conclusions were drawn in recent studies of a panel of primary leukemic blasts with variable degrees of Apaf-1 expression. 5 However, although the latter study reported a correlation between total cellular levels Apaf-1 and responsiveness to Smac peptides, we have conclusively shown that the restoration of cytosolic Apaf-1 expression in lymphoma cells, either through overexpression of Apaf-1 in these cells or through lipid raft disruption and liberation of endogenous Apaf-1, is required for the proapoptotic effect of Smac peptides.
Elegant recent studies performed in a pheochromocytoma cell line have indicated that cell differentiation is linked to a reciprocal regulation of Apaf-1 and IAPs, insofar as a decrease in Apaf-1 expression was observed concomitant with an increased ability of IAPs to regulate apoptosis. 25 On the basis of these findings, it was concluded that the efficiency of the apoptosome sets the threshold for IAPs to inhibit apoptosis in neurons. The prediction from such a model is that cells with a reduced level of Apaf-1 (such as the Raji cell line) are subject to strict regulation of cytochrome c-dependent apoptosis by endogenous IAPs. Indeed, some recent studies have suggested that cancer cells have an intrinsic drive to activate caspases that is held in check by IAPs, whereas normal cells are less dependent on IAPmediated apoptosis inhibition. 26, 27 However, as mentioned above, our findings provide evidence that apoptosome activation is crucial for apoptosis of non-Hodgkin's lymphoma cells, and suggest that the depletion of IAPs from cellular extracts, or modulation of IAPs in intact cells through the introduction of exogenous Smac peptides, is insufficient to restore sensitivity to apoptosis, unless Apaf-1 is also expressed in the cytosol of these cells. Studies from other investigators 15 demonstrating the To conclude, we have provided evidence that cytosolic Apaf-1 expression is required for Smac-dependent potentiation of apoptosis of human B-lymphoma cells. Our results also demonstrate that the endogenous caspase inhibitor, cIAP2, may serve to modulate the sensitivity to cytochrome cdependent caspase activation in these cells. Moreover, apoptosis triggered by lactacystin, a specific inhibitor of the proteasome, was shown to be Apaf-1-dependent in the model cell lines used herein. On the basis of these current results, we surmise that small molecule IAP antagonists 27 and Smac mimetics 28 may be beneficial as adjuvant treatment modalities in B lymphomas and other malignancies that express functional Apaf-1 in the cytosol. Furthermore, B lymphomas that display ectopic expression of Apaf-1 in the plasma membrane, 11 could perhaps be sensitized to Smac-and/or IAP-targeted therapies through the disruption of lipid raft domains, with the subsequent liberation of Apaf-1 into the cytosol.
